Dr. John Walker, MD
Claim this profileCross Cancer Institute
Studies Cancer
Studies Melanoma
5 reported clinical trials
12 drugs studied
Area of expertise
1Cancer
Stage IV
Stage I
Stage II
2Melanoma
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials John Walker, MD is currently running
PD-1 Inhibitor Therapy Duration
for Melanoma
The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of treatment work equally well in extending the life of patients with melanoma, or not.
Recruiting2 awards Phase 39 criteria
Immunotherapy with Steroids
for Brain Metastases
Immunotherapy treatments are intended to boost a person's immune system to fight their cancer. Treatment with immunotherapy has been shown to be effective in a wide range of cancers, including melanoma skin cancer, lung cancer and kidney cancer, among others. Steroids are anti-inflammatory medications which may suppress the immune system. For this reason, persons requiring treatment with steroids have not previously been allowed to participate in immunotherapy clinical trials. Therefore, we do not know whether or not immunotherapy treatments are effective in patients who are also receiving treatment with steroids. When cancer has spread to the brain swelling may occur around the tumors, and headache, nausea, seizures or stroke-like symptoms may occur. In this instance, steroids are important to reduce swelling within the brain, thus alleviating these symptoms. Because patients requiring treatment with steroids have not previously been allowed to participate in immunotherapy clinical trials, we do not know whether treatment with immunotherapy is effective when steroid treatments are also used. This study will investigate this question, and also attempt to determine whether treatment with one steroid versus another results in a better response to immunotherapy.
Recruiting1 award Phase 213 criteria
More about John Walker, MD
Clinical Trial Related7 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments John Walker, MD has experience with
- BMS-986253
- Ipilimumab
- Nivolumab
- Cisplatin
- Durvalumab
- Tremelimumab
Breakdown of trials John Walker, MD has run
Cancer
Squamous Cell Carcinoma
Brain Metastases
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John Walker, MD specialize in?
John Walker, MD focuses on Cancer and Melanoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage I.
Is John Walker, MD currently recruiting for clinical trials?
Yes, John Walker, MD is currently recruiting for 2 clinical trials in Edmonton Alberta. If you're interested in participating, you should apply.
Are there any treatments that John Walker, MD has studied deeply?
Yes, John Walker, MD has studied treatments such as BMS-986253, Ipilimumab, Nivolumab.
What is the best way to schedule an appointment with John Walker, MD?
Apply for one of the trials that John Walker, MD is conducting.
What is the office address of John Walker, MD?
The office of John Walker, MD is located at: Cross Cancer Institute, Edmonton, Alberta T6G 1Z2 Canada. This is the address for their practice at the Cross Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.